DNA demethylases: a new epigenetic frontier in drug discovery - PubMed (original) (raw)
Review
. 2011 Aug;16(15-16):683-90.
doi: 10.1016/j.drudis.2011.05.004. Epub 2011 May 13.
Affiliations
- PMID: 21601651
- DOI: 10.1016/j.drudis.2011.05.004
Review
DNA demethylases: a new epigenetic frontier in drug discovery
Nessa Carey et al. Drug Discov Today. 2011 Aug.
Abstract
DNA methylation is one of the most extensively studied, and one of the most stable, of all epigenetic modifications. Two drugs that target DNA methyltransferase enzymes are licensed for clinical use in oncology but relatively little attention has focused on the enzymatic pathways by which DNA methylation can be reversed. Recent breakthroughs have identified at least two classes of enzymes that can achieve functional reversal. This review discusses the significance of DNA demethylation in a range of human diseases, the candidate proteins that mediate the demethylation and the opportunities and challenges in targeting these candidates to develop new therapeutics.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
- Epigenetic small molecule modulators of histone and DNA methylation.
Hauser AT, Robaa D, Jung M. Hauser AT, et al. Curr Opin Chem Biol. 2018 Aug;45:73-85. doi: 10.1016/j.cbpa.2018.03.003. Epub 2018 Mar 24. Curr Opin Chem Biol. 2018. PMID: 29579619 Review. - Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation.
Liu K, Liu Y, Lau JL, Min J. Liu K, et al. Pharmacol Ther. 2015 Jul;151:121-40. doi: 10.1016/j.pharmthera.2015.04.001. Epub 2015 Apr 7. Pharmacol Ther. 2015. PMID: 25857453 Review. - Epigenetic opportunities and challenges in cancer.
Best JD, Carey N. Best JD, et al. Drug Discov Today. 2010 Jan;15(1-2):65-70. doi: 10.1016/j.drudis.2009.10.010. Epub 2009 Nov 6. Drug Discov Today. 2010. PMID: 19897050 Review. - Epigenetic protein families: a new frontier for drug discovery.
Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Arrowsmith CH, et al. Nat Rev Drug Discov. 2012 Apr 13;11(5):384-400. doi: 10.1038/nrd3674. Nat Rev Drug Discov. 2012. PMID: 22498752 Review. - Epigenetic agents in combined anticancer therapy.
Kejík Z, Jakubek M, Kaplánek R, Králová J, Mikula I, Martásek P, Král V. Kejík Z, et al. Future Med Chem. 2018 May 1;10(9):1113-1130. doi: 10.4155/fmc-2017-0203. Epub 2018 Apr 20. Future Med Chem. 2018. PMID: 29676175 Review.
Cited by
- Theoretical cross-comparative analysis on dynamics of small intestine and colon crypts during cancer initiation.
Roznovăţ IA, Ruskin HJ. Roznovăţ IA, et al. IET Syst Biol. 2015 Dec;9(6):259-67. doi: 10.1049/iet-syb.2015.0048. IET Syst Biol. 2015. PMID: 26577160 Free PMC article. - The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.
Yang Q, Mas A, Diamond MP, Al-Hendy A. Yang Q, et al. Reprod Sci. 2016 Feb;23(2):163-75. doi: 10.1177/1933719115584449. Epub 2015 Apr 28. Reprod Sci. 2016. PMID: 25922306 Free PMC article. Review. - Exercise Ameliorates Spinal Cord Injury by Changing DNA Methylation.
Davaa G, Hong JY, Kim TU, Lee SJ, Kim SY, Hong K, Hyun JK. Davaa G, et al. Cells. 2021 Jan 12;10(1):143. doi: 10.3390/cells10010143. Cells. 2021. PMID: 33445717 Free PMC article. - Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy.
Elmallah MIY, Micheau O. Elmallah MIY, et al. Cancers (Basel). 2019 Jun 19;11(6):850. doi: 10.3390/cancers11060850. Cancers (Basel). 2019. PMID: 31248188 Free PMC article. Review. - Global hypermethylation in fetal cortex of Down syndrome due to DNMT3L overexpression.
Lu J, Mccarter M, Lian G, Esposito G, Capoccia E, Delli-Bovi LC, Hecht J, Sheen V. Lu J, et al. Hum Mol Genet. 2016 May 1;25(9):1714-27. doi: 10.1093/hmg/ddw043. Epub 2016 Feb 23. Hum Mol Genet. 2016. PMID: 26911678 Free PMC article.